ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1,2,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
2,1,Intermenstrual bleeding,Menstruation and uterine bleeding NEC,Menstrual cycle and uterine bleeding disorders,Repro,N
3,1,Asthma,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
4,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4,2,Unintended pregnancy,Unintended pregnancies,"Pregnancy, labour, delivery and postpartum conditions",Preg,N
5,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
5,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
5,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
6,1,Pancreatitis acute,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
7,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
7,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
7,3,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
8,1,Proctitis,Rectal inflammations NEC,Gastrointestinal inflammatory conditions,Gastr,N
